PMN: Assayed External Control Material For Microbiology Nucleic Acid Amplification (Nat) Assays
What it covers
Assayed external quality control material to monitor the performance of microbiology nucleic acid assays for in vitro diagnostic use.
FDA’s definition of product code PMN, from the Product Classification database.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K261475 | BIOFIRE® FILMARRAY® Tropical Fever Panel Control Kit | Biofire Defense, LLC | Jul 17, 2026 | Traditional |
| K260577 | FilmArray TF Control Panel M527 | Maine Molecular Quality Controls, Inc. | May 19, 2026 | Traditional |
| K260041 | MDx-Chex for BCP | Streck, LLC | Mar 27, 2026 | Traditional |
| K254166 | MDx-Chex for BCN | Streck | Mar 23, 2026 | Traditional |
| K254167 | MDx-Chex for BCY | Streck, LLC | Mar 17, 2026 | Traditional |
| K251526 | FilmArray GI Control Panel M238 | Maine Molecular Quality Controls, Inc. | Aug 14, 2025 | Traditional |
| K241289 | SPOTFIRE RSP Pos & Neg Controls; SPOTFIRE RSP Negative Control | Maine Molecular Quality Controls, Inc. | May 30, 2024 | Special |
| K233611 | SPOTFIRE RSP Pos & Neg Controls (M425), SPOTFIRE RSP Positive Control (M42638), SPOTFIRE RSP Negative Control (M42738) | Maine Molecular Quality Controls, Inc. | Mar 26, 2024 | Traditional |
| K231221 | MDx-Chex for BC-GP | Streck | Jul 27, 2023 | Traditional |
| K231223 | MDx-Chex for BC-GN | Streck | Jul 27, 2023 | Traditional |
Clearances by year
32 PMN 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 5 | 84 |
| 2025 | 1 | 87 |
| 2024 | 2 | 79 |
| 2023 | 4 | 90 |
| 2022 | 3 | 582 |
| 2021 | 1 | 323 |
| 2020 | 2 | 92 |
| 2019 | 6 | 71 |
| 2018 | 3 | 59 |
| 2017 | 2 | 73 |
| 2016 | 3 | 103 |
Who submits
8 applicants cleared a PMN device since 2011. 100% of the clearances went to applicants in United States. By type: Traditional 91%, Special 6% and Post-NSE 3%.
| Applicant | Clearances since 2011 |
|---|---|
| Maine Molecular Quality Controls, Inc. | 13 |
| Microbiologics, Inc. | 8 |
| Streck | 3 |
| Bio-Rad Laboratories | 2 |
| Biofire Defense, LLC | 2 |
| Streck, LLC | 2 |
| Streck, Inc. | 1 |
| Zeptometrix | 1 |
How FDA classifies it
Class II (special controls). The special controls for this device are:
(1) Premarket notification submissions must include detailed device description documentation and information concerning the composition of the quality control material, including, as appropriate:
(i) Analyte concentration;
(ii) Expected values;
(iii) Analyte source;
(iv) Base matrix;
(v) Added components;
(vi) Safety and handling information; and
(vii) Detailed instructions for use.
(2) Premarket notification submissions must include detailed documentation, including line data as well as detailed study protocols and a statistical analysis plan used to establish performance, including:
(i) Description of the process for value assignment and validation.
(ii) Description of the protocol(s) used to establish stability.
(iii) Line data establishing precision/reproducibility.
(iv) Where applicable, assessment of matrix effects and any significant differences between the quality control material and typical patient samples in terms of conditions known to cause analytical error or affect assay performance.
(v) Where applicable, identify or define traceability or relationship to a domestic or international standard reference material and/or method.
(vi) Where applicable, detailed documentation related to studies for surrogate controls.
(3) Premarket notification submissions must include an adequate mitigation (e.g., real-time stability program) to the risk of false results due to potential modifications to the assays specified in the device's 21 CFR 809.10 compliant labeling.
(4) Your 21 CFR 809.10 compliant labeling must include the following:
(i) The intended use of your 21 CFR 809.10(a)(2) and (b)(2) compliant labeling must include the following:
(A) Assayed control material analyte(s);
(B) Whether the material is intended for quantitative or qualitative assays;
(C) Stating if the material is a surrogate control; and
(D) The system(s), instrument(s), or test(s) for which the quality control material is intended.
(ii) The intended use in your 21 CFR 809.10(a)(2) and (b)(2) compliant labeling must include the following statement: “This product is not intended to replace manufacturer controls provided with the device.”
(iii) A limiting statement that reads “Quality control materials should be used in accordance with local, state, federal regulations, and accreditation requirements.”
From 21 CFR 866.3920. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 866.3920 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent PMN clearances declared.
Ask about PMN
Questions about PMN
What is FDA product code PMN?
Product code PMN, “Assayed External Control Material For Microbiology Nucleic Acid Amplification (Nat) Assays” in FDA's classification database, is a Class II device type under 21 CFR 866.3920 (assayed quality control material for clinical microbiology assays), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 32 clearances under PMN, 32 of them since 2011.
How many 510(k) clearances are there under PMN?
FDA’s 510(k) database listed 32 clearances under PMN as of Oct 29, 2026, 32 of them decided since 2011; the most recent decision was Jul 17, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a PMN 510(k)?
For the 6 PMN clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 86 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most PMN clearances?
Since 2011: Maine Molecular Quality Controls, Inc. (13), Microbiologics, Inc. (8), Streck (3), Bio-Rad Laboratories (2) and Biofire Defense, LLC (2). 8 applicants have cleared a PMN device in that time.